Optimizing Biktarvy Prior Authorization for Dermatology Practices

Navigating High-Volume Prior Authorizations in Dermatology

While dermatology practices primarily focus on conditions requiring biologics, specialty topicals, or procedures like Mohs surgery, they frequently encounter prior authorization requests for other high-volume specialty drugs. Medications like Biktarvy, though not typically prescribed for dermatological conditions, still require diligent PA management when patients present with such prescriptions, adding to the administrative burden. Klivira’s platform is designed to handle this diverse range of PA requirements across all payer types.

Core Prior Authorization Triggers in Dermatology

• Biologics for chronic conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa
• Specialty topicals and advanced skin cancer treatments
• Mohs micrographic surgery for non-melanoma skin cancers in sensitive areas
• Periodic re-authorization for ongoing biologic treatments
• Medical-vs-pharmacy benefit routing for self-injection versus clinic infusion

Key Documentation for Dermatology Prior Authorizations

• Diagnosis confirmation with severity scores (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis)
• Documentation of prior topical therapy trials, phototherapy trials, or conventional systemic therapy trials
• Pre-biologic screenings (e.g., TB, hepatitis) where applicable per payer policy
• Conformance with Appropriate Use Criteria (e.g., AAD AUC for Mohs surgery)
• Evidence of disease progression or failure of less intensive therapies

Mitigating Common Dermatology PA Denials

• Insufficient documentation of step therapy compliance for biologics
• Lack of documented disease severity or specific diagnostic criteria
• Mismatched Mohs AUC indications for site or tumor type
• Missing pre-biologic screening results prior to therapy initiation
• Payer preference for biosimilar substitution over originator biologics

Klivira: Streamlining Prior Authorization Across Dermatology Workflows

Klivira’s platform integrates with leading EMRs, automating the submission and tracking of prior authorizations for high-volume drugs and procedures common in dermatology. Our system incorporates AAD guideline-aware logic for biologics, validates AUC for Mohs surgery, and manages periodic re-authorization cycles. This reduces manual tasks, minimizes human error, and ensures that all necessary documentation is presented correctly to payers, whether for a dermatological biologic or a specialty drug like Biktarvy.

Seamless Integration for Enhanced Revenue Cycle Management

By leveraging SMART on FHIR and X12 278 standards, Klivira connects directly with EMRs and payer portals, including ePA and NCPDP SCRIPT channels. This comprehensive connectivity ensures that patient data is securely exchanged, and PA requests for all medications, including Biktarvy, are routed efficiently. Dermatology practices can reallocate staff from administrative PA tasks to patient care, optimizing their revenue cycle operations without compromising compliance or patient access.